The Company has rights to an invention covered by a non-provisional patent application disclosing compositions of matter, protocols and methods of use of treatment for cancer and other diseases of aberrant cellular proliferation. The patent covers the use of its proprietary novel candidates administered as short interfering nucleic acid antisense, short interfering RNA , double-stranded RNA , micro-RNA , and short hairpin RNA .
http://ift.tt/1DBAoMz
http://ift.tt/1DBAoMz
No comments:
Post a Comment